GSK plc (GSKL.XC)
| Previous close | 1,526.00 |
| Open | 1,538.50 |
| Bid | 1,530.50 x N/A |
| Ask | 1,531.50 x N/A |
| Day's range | 1,523.00 - 1,540.50 |
| 52-week range | 1,302.90 - 1,820.00 |
| Volume | |
| Avg. volume | 1,066,965 |
| Market cap | 62.476B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 1,405.50 |
| EPS (TTM) | 1.09 |
| Earnings date | 31 Jul 2024 |
| Forward dividend & yield | 0.60 (3.93%) |
| Ex-dividend date | 16 May 2024 |
| 1y target est | N/A |
Insider MonkeyGSK plc (GSK): Did This Healthcare Stock Show a Strong Performance in Q1?
We recently compiled a list of the 10 Best Healthcare Stocks to Buy Under $50. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other healthcare stocks under $50. If interested, you can also read our recent article on the 10 Best Healthcare Stocks To Buy […]
- Yahoo Finance Video
GSK stock falls as CDC shifts RSV vaccine recommendation
Shares of GSK (GSK) are falling after a Centers for Disease Control and Prevention (CDC) committee shifted its recommendation on Respiratory Syncytial Virus (RSV) vaccination dosages. Yahoo Finance reporter Anjalee Khemlani joins Morning Brief to break down this latest development for GSK and what the CDC announcement could mean for the company moving forward. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Nicholas Jacobino.
- Investing.com
Moderna shares decline, RSV vaccine efficacy lags behind competitors
Investing.com - Moderna Inc (NASDAQ:MRNA) experienced an 11% drop on Wednesday after the company disclosed that its respiratory syncytial virus (RSV) vaccine, mResvia, exhibited 50% efficacy in preventing the illness 18 months post-administration.
